Compare DFLI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | NSPR |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | DFLI | NSPR |
|---|---|---|
| Price | $3.51 | $1.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | $4.00 |
| AVG Volume (30 Days) | ★ 1.0M | 58.9K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,783,000.00 | $7,779,000.00 |
| Revenue This Year | $17.85 | $22.76 |
| Revenue Next Year | $30.29 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.24 | 14.04 |
| 52 Week Low | $1.50 | $1.59 |
| 52 Week High | $38.90 | $3.80 |
| Indicator | DFLI | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 67.37 | 44.57 |
| Support Level | $0.41 | $1.89 |
| Resistance Level | $4.23 | $2.17 |
| Average True Range (ATR) | 0.34 | 0.15 |
| MACD | 0.29 | 0.01 |
| Stochastic Oscillator | 64.44 | 34.88 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.